ReviewThe AAPS journal2009
Lipidic systems for in vivo siRNA delivery.
Review in The AAPS journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Article
- Ambient-Stable mRNA Medicines: Emerging Paradigms in Dry and Solid-State Formulation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Astonishing Accomplishment of Biological Drug Delivery using Lipid Nanoparticles: An Ubiquitous Review.Current pharmaceutical biotechnology · 2024Review
- Impact of Peptide Sequence on Functional siRNA Delivery and Gene Knockdown with Cyclic Amphipathic Peptide Delivery Agents.Molecular pharmaceutics · 2023Article
- A novel method for the development of plasmid DNA-loaded nanoliposomes for cancer gene therapy.Drug delivery and translational research · 2022Article
- Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy.Drug delivery and translational research · 2022Review
- Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.The AAPS journal · 2021Article
- Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives.Bioengineering & translational medicine · 2021Review
- DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.Pharmaceutics · 2020Review
- Delivery of Functional Small RNAs via Extracellular Vesicles In Vitro and In Vivo.Methods in molecular biology (Clifton, N.J.) · 2020Article
- RNAi therapeutic strategies for acute respiratory distress syndrome.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach.International journal of nanomedicine · 2019Review
- A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice.PloS one · 2019Article
- Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice.Molecular therapy. Nucleic acids · 2018Article
- Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities.Nanomaterials (Basel, Switzerland) · 2018Review
- Practical Use of RNA Interference: Oral Delivery of Double-stranded RNA in Liposome Carriers for Cockroaches.Journal of visualized experiments : JoVE · 2018Article
- Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.Drug delivery and translational research · 2017Review
- Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems.Kona : powder science and technology in Japan · 2017Article
- Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine.Bioengineering & translational medicine · 2016Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability of small-interfering RNA (siRNA) to silence specific target genes not only offers a tool to study gene function but also represents a novel approach for the treatment of various human diseases. Its clinical use, however, has been severely hampered by the lack of delivery of these molecules to target cell populations in vivo due to their instability, inefficient cell entry, and poor pharmacokinetic profile. Various delivery vectors including liposomes, polymers, and nanoparticles have thus been developed in order to circumvent these problems. This review presents a comprehensive overview of the barriers and recent progress for both local and systemic delivery of therapeutic siRNA using lipidic vectors. Different strategies for formulating these siRNA-loaded lipid particles as well as the general concern about their safe use in vivo will also be discussed. Finally, current advances in the targeted delivery of siRNA and their impacts on the field of RNA interference (RNAi)-based therapy will be presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.